Planet Briefing

First published · Last updated

Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran

Journal article published by Elsevier presenting a cost-effectiveness comparison of carfilzomib versus bortezomib for relapsed/refractory multiple myeloma in Iran. The supplied source data include no methodological details, sample sizes, or results.

Categories: public-health, economy-and-trade

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
6/10
Geographic reach
4/10
Global importance
3/10
Impact magnitude
3/10
Positivity
6/10
Urgency
2/10

Why it matters

It matters because it reports a cost-effectiveness comparison of cancer treatments specific to Iran.

Location

Sources

Report an issue